Home > Journals > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Past Issues > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2017 June;61(2) > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2017 June;61(2):232-46

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as

 

REVIEW   

The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2017 June;61(2):232-46

DOI: 10.23736/S1824-4785.16.02735-7

Copyright © 2016 EDIZIONI MINERVA MEDICA

language: English

Clinical application of FDG-PET/CT in metastatic infections

Ilse J. KOUIJZER 1, Fidel J. VOS 1, 2, Chantal P. BLEEKER-ROVERS 1, Wim J. OYEN 3

1 Department of Internal Medicine, Radboud University Medical Center, Nijmegen, The Netherlands; 2 Sint Maartenskliniek, Nijmegen, The Netherlands; 3 Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, The Netherlands


PDF


FDG-PET/CT has proven its clinical value and cost-effectiveness in diagnosing metastatic infections in patients with Gram-positive bacteremia. In identification of metastatic foci, FDG-PET/CT is useful as a screening method when localizing symptoms are absent because it provides whole-body coverage. FDG-PET/CT detects early metabolic activity rather than the late anatomical changes as visualized by computed tomography and magnetic resonance imaging. FDG-PET/CT allows more precise localization of infection within a shorter time span between injection and diagnosis as compared to conventional nuclear imaging. This review focuses on the clinical application of imaging of metastatic infectious diseases, with an emphasis on FDG-PET/CT putting it in perspective with other imaging modalities.


KEY WORDS: Fluorodeoxyglucose F18 - Positron-emission tomography - Computed tomography - Metastatic infection - Bacteremia - Diagnostic imaging

top of page